Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1093/NAR/GKAB1188 | ||||
| Año | 2022 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Translation initiation of the viral genomic mRNA (vRNA) of human immunodeficiency virus-type 1 (HIV-1) can be mediated by a cap- or an internal ribosome entry site (IRES)-dependent mechanism. A previous report shows that Staufen1, a cellular double-stranded (ds) RNA-binding protein (RBP), binds to the 5'untranslated region (5'UTR) of the HIV-1 vRNA and promotes its cap-dependent translation. In this study, we now evaluate the role of Staufen1 as an HIV-1 IRES-transacting factor (ITAF). We first confirm that Staufen1 associates with both the HIV-1 vRNA and the Gag protein during HIV-1 replication. We found that in HIV-1-expressing cells, siRNA-mediated depletion of Staufen1 reduces HIV-1 vRNA translation. Using dual-luciferase bicistronic mRNAs, we show that the siRNA-mediated depletion and cDNA-mediated overexpression of Staufen1 acutely regulates HIV-1 IRES activity. Furthermore, we show that Staufenl-vRNA interaction is required for the enhancement of HIV-1 IRES activity. Interestingly, we find that only Staufen1 harboring an intact dsRNA-binding domain 3 (dsRBD3) rescues HIV-1 IRES activity in Staufen1 CRISPR-Cas9 gene edited cells. Finally, we show that the expression of Staufen1-dsRBD3 alone enhances HIV-1 IRES activity. This study provides evidence of a novel role for Staufen1 as an ITAF promoting HIV-1 vRNA IRES activity.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Ramos, Hade | - |
Pontificia Universidad Católica de Chile - Chile
Escuela de Medicina - Chile |
| 2 | Monette, Anne | Mujer |
Jewish Gen Hosp - Canadá
Lady Davis Institute for Medical Research - Canadá Institut Lady Davis de Recherches Médicales - Canadá |
| 3 | Niu, Meijuan | - |
Jewish Gen Hosp - Canadá
Lady Davis Institute for Medical Research - Canadá Institut Lady Davis de Recherches Médicales - Canadá |
| 4 | BARRERA-VASQUEZ, ALDO VICENT | Hombre |
Pontificia Universidad Católica de Chile - Chile
Escuela de Medicina - Chile |
| 5 | Lopez-Ulloa, Brenda | Mujer |
Pontificia Universidad Católica de Chile - Chile
Escuela de Medicina - Chile |
| 6 | Fuentes, Yazmin | Mujer |
Pontificia Universidad Católica de Chile - Chile
Lady Davis Institute for Medical Research - Canadá School of Medicine - Canadá Institut Lady Davis de Recherches Médicales - Canadá |
| 7 | Guizar, Paola | Mujer |
Jewish Gen Hosp - Canadá
MCGILL UNIV - Canadá Escuela de Medicina - Chile |
| 8 | PINO-LEMUNAO, KARLA CAROLINA | Mujer |
Pontificia Universidad Católica de Chile - Chile
University of Montreal - Canadá |
| 9 | DesGroseillers, Luc | - |
UNIV MONTREAL - Canadá
University of Montreal - Canadá |
| 10 | Mouland, Andrew J. | Hombre |
Jewish Gen Hosp - Canadá
MCGILL UNIV - Canadá Lady Davis Institute for Medical Research - Canadá School of Medicine - Canadá Institut Lady Davis de Recherches Médicales - Canadá |
| 11 | LÓPEZ-LASTRA, MARCELO | Hombre |
Pontificia Universidad Católica de Chile - Chile
Escuela de Medicina - Chile |
| Fuente |
|---|
| FONDECYT |
| Gobierno de Chile |
| Canadian Institutes of Health Research (CIHR) |
| Agencia Nacional de Investigacion y Desarrollo (ANID) |
| Vicerrectoria de Investigacion (VRI), PUC |
| ANID-Doctoral Fellowship |
| Iniciativa Cientifica Milenio (ICM), Instituto Milenio de Inmunologia e Inmunoterapia |
| Lady Davis Institute at the Jewish General Hospital (Montreal, Canada) |
| Mexican Instituto de Financiamiento e Informacion para la Educacion (EDUCAFIN) |
| Agradecimiento |
|---|
| The work was supported by the Agencia Nacional de Investigacion y Desarrollo (ANID); Gobierno de Chile [FONDECYT 1170590 and FONDECYT 1210736] to M.L-L.; Iniciativa Cientifica Milenio (ICM), Instituto Milenio de Inmunolog ' ia e Inmunoterapia [P09/016-F; ICN09 016 to M.L-L.]; Canadian Institutes of Health Research (CIHR) [FRN-56974 and FRN-162447 to A.J.M.]. M.N. was supported by generous funding from the Lady Davis Institute at the Jewish General Hospital (Montreal, Canada); P.G. was supported by a scholarship from the Mexican Instituto de Financiamiento e Informaci ' on para la Educaci ' on (EDUCAFIN); B.L-U. was supported by a Doctoral Fellowship from the Vicerrector ' ia de Investigaci ' on (VRI), PUC; Y.F. was supported by ANID-Doctoral Fellowship 21191169. Funding for open access charge: FONDECYT [1210736]. |